RedHill Biopharma Reports $4.3M Equity Turnaround, $4M Talicia JV and $60M Bekinda Deal
RedHill Biopharma ended 2025 with positive equity of $4.3M and $4.1M cash after Cumberland’s $4M investment for 30% of newly formed Talicia Holdings Inc. The company secured up to $60M in milestone payments plus royalties for RHB-102 ex-North America and generated $1.9M in Middle East Talicia sales.
1. Equity and Liquidity
RedHill closed 2025 with positive shareholders’ equity of $4.3 million, a turnaround from a $4.7 million deficiency at end-2024. The company reported a cash balance of $4.1 million as of December 31, 2025, and secured a $10 million line of credit with Alumni Capital LP.
2. Talicia Holdings Joint Venture
RedHill transferred its Talicia® commercial operations to Talicia Holdings Inc., retaining 70% ownership while Cumberland Pharmaceuticals invested $4 million for a 30% stake. The partnership added eight million Humana Part D covered lives, supported a three-times-daily dosing label update, and drove $1.9 million in Middle East revenues, with a UK fast-track MAA submission imminent.
3. RHB-102 Licensing and Financings
The company licensed RHB-102 (Bekinda®) ex-North America to Hyloris for up to $60 million in milestone payments plus royalties, generating $0.3 million in upfront revenue. RedHill also won a $10.5 million final judgment in Kukbo litigation, subject to collection, and holds a contingent ADS sale facility with Alumni Capital.
4. R&D Pipeline Advances
The Crohn’s disease candidate RHB-204 progressed under FDA guidance, accompanied by two new MAP diagnostic collaborations. Opaganib is in Phase 2 trials combined with darolutamide in mCRPC, with additional preclinical data reported in CLL, neuroblastoma and TNBC, and discussions for pediatric oncology partnerships ongoing.